NCT05660369View on ClinicalTrials.gov

CARv3-TEAM-E T Cells in Glioblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
GlioblastomaMalignant GliomaRecurrent GlioblastomaRecurrent Glioma
Interventions
DRUG

CARv3-TEAM-E T cells

Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.

Trial Locations (1)

02215

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
lead

Marcela V. Maus, M.D.,Ph.D.

OTHER